Details of the Drug

General Information of Drug (ID: DM571JP)

• Drug Name: PMID29473428-Compound-15
• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 317.72
  Logarithm of the Partition Coefficient (xlogp); 3.8
  Rotatable Bond Count (rotbonds); 3
  Hydrogen Bond Donor Count (hbonddonor); 1
  Hydrogen Bond Acceptor Count (hbondacc); 5
• Chemical Identifiers:
  Formula: C15H12ClN3O3
  IUPAC Name: phenyl N-(5-chloro-4,6-dimethyl-[1,2]oxazolo[5,4-b]pyridin-3-yl)carbamate
  Canonical SMILES: CC1=C2C(=NOC2=NC(=C1Cl)C)NC(=O)OC3=CC=CC=C3
  InChI: InChI=1S/C15H12ClN3O3/c1-8-11-13(19-22-14(11)17-9(2)12(8)16)18-15(20)21-10-6-4-3-5-7-10/h3-7H,1-2H3,(H,18,19,20)
  InChIKey: WUNZBHVIWUQNNS-UHFFFAOYSA-N
• Cross-matching ID:
  PubChem CID: 126640018
  TTD ID: D0DW4P

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Indoleamine 2,3-dioxygenase 1 (IDO1)	TTZJYKH	I23O1_HUMAN	Inhibitor	[1]

References

• [1] A patent review of IDO1 inhibitors for cancer.Expert Opin Ther Pat. 2018 Apr;28(4):317-330.